A message from Mike Martin, President and CEO, ISPE - In late May, I had the distinct pleasure of visiting 中外製薬工業株式会社 Chugai Pharmaceutical Manufacturing Co., Ltd.’s UK4 biological drug substance manufacturing facility in Tokyo, Japan—Category Winner of the 2024 ISPE Facility of the Year Awards (FOYA) in Social Impact. This visit was not only inspiring but also a powerful reminder of the innovation and dedication that define the future of pharmaceutical manufacturing. Read more in this iSpeak blog: https://bit.ly/4jyXFbb (fb)

The 2025 ISPE Biotechnology Conference opened with a compelling series of presentations. Mike Martin, President and CEO, ISPE welcomed attendees with opening remarks, setting the tone for the event. James Grunwald shared key updates and initiatives from the ISPE Foundation. Magaly Aham explored AI as an enabler for a sustainable quality transformation, while Oliver Thiel addressed current challenges in biomanufacturing with reliability, efficiency, agility, and differentiation. Eamonn Warren concluded the opening sessions by highlighting the significance of a holistic digital strategy that incorporates AI, machine learning, predictive modeling, and data visualization. There’s still time to join virtually—plus all virtual attendees receive access to On Demand session recordings following the conference. Register now: https://bit.ly/4kPjSmo (fb)